UK, Morvus Technology Completes £2.15M Funding Round

Morvus Technology Ltd, a Llanarthne, South Wales-based pharmaceutical company specialising in the discovery and commercialisation of novel drugs for the oncology market, has completed a £2.15m funding round.
Morvus, a portfolio company of Fusion IP (AIM: FIP), the university commercialisation company aimed to turn university research into business, will use the funds to progress its main drug development programs.
Early in November, Morvus signed an exclusive licensing agreement with NuCana BioMed Ltd, which grants NuCana the right to develop Morvus’ ProTide technology for the enhancement of nucleoside analogues (nucleosides are drugs used in the treatment of many common cancers).
The agreement will grant the company rights, payments and royalties resulting from the commercialisation of the technology.

Join the discussion